Nirmatrelvir-D9
| Product Name | Nirmatrelvir-D9 |
|---|---|
| Alternate Names | Nirmatrelvir Stable Isotopes, Stable Isotopes of Nirmatrelvir |
| CAT No. | CS-O-40426 |
| CAS No. | 2628280-40-8 (Unlabeled) |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 508.58 g/mol |
| Mol. For. | C₂₃H₂₃D₉F₃N₅O₄ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Nirmatrelvir |
| Canonical Smiles | CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)C(F)(F)F)C(=O)NC(CC3CCNC3=O)C#N)C |
| InchIKey | LIENCHBZNNMNKG-OJFNHCPVSA-N |
| Inchl | InChI=1S/C23H32F3N5O4/c1-21(2,3)16(30-20(35)23(24,25)26)19(34)31-10-13-14(22(13,4)5)15(31)18(33)29-12(9-27)8-11-6-7-28-17(11)32/h11-16H,6-8,10H2,1-5H3,(H,28,32)(H,29,33)(H,30,35)/t11-,12-,13-,14-,15-,16+/m0/s1 |
| IUPAC | (1R,2S,5S)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Nirmatrelvir-D9 is a deuterated form of the antiviral drug Nirmatrelvir, which is used in combination with other drugs to treat patients with COVID-19. This medication is classified as a protease inhibitor, which means it works by blocking the action of a specific enzyme that is needed by the virus to replicate and spread. By inhibiting this enzyme, Nirmatrelvir-D9 can help to reduce the severity of symptoms and shorten the duration of illness.
Chemically, Nirmatrelvir-D9 is a derivative of the original drug Nirmatrelvir, which contains hydrogen atoms in place of deuterium atoms. Deuterium is a stable isotope of hydrogen that is twice as heavy, making Nirmatrelvir-D9 a labeled compound that can be easily tracked and measured through scientific studies.
In clinical trials, Nirmatrelvir-D9 has shown promising results in reducing viral load and improving clinical outcomes in COVID-19 patients. This medication is typically administered orally and is generally well-tolerated, although some patients may experience side effects such as nausea, diarrhea, and headache.
Overall, Nirmatrelvir-D9 represents a promising new treatment option for patients with COVID-19 and may play an important role in helping to control the spread of the virus. Ongoing research is needed to fully understand the safety and effectiveness of this medication, but early results are encouraging and suggest that it may be a valuable tool in the fight against COVID-19.
Get an Instant Quote
Related Compounds
Nirmatrelvir-D6 | Nirmatrelvir-D9 |